NASDAQ: ADTXAditxt Inc Stock
$1.70-0.14 (-7.61%)
Updated May 8, 2025
ADTX Price
$1.70
Fair Value Price
N/A
Market Cap
$1.97M
52 Week Low
$1.51
52 Week High
$27,200.00
P/E
0x
P/B
3.97x
P/S
4.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$133.99k
Earnings
-$40.35M
Gross Margin
-368.3%
Operating Margin
-26,991.66%
Profit Margin
-34,526.6%
Debt to Equity
48.05
Operating Cash Flow
-$17M
Beta
0.54
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ADTX Overview
Aditxt, Inc. is a biotech company developing technologies to improve the health of the immune system by mapping and reprogramming. Its products, AditxtScore and Apoptotic DNA Immunotherapy, mimic the way the body naturally induces tolerance. Aditxt is also developing organ transplant products. The company has a license agreement with Loma Linda University. It was known as ADiTx Therapeutics, Inc. until it changed its name in 2021/07. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, VA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADTX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADTX
Ranked#258 of 457
Ranked#258 of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important ADTX news, forecast changes, insider trades & much more!
ADTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADTX is good value based on its book value relative to its share price (3.97x), compared to the US Biotechnology industry average (4.15x)
P/B vs Industry Valuation
ADTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ADTX due diligence checks available for Premium users.
Valuation
ADTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-168.76x
Market
24.22x
ADTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.97x
Industry
4.15x
ADTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADTX's financial health
Profit margin
Revenue
$3.2k
Net Income
-$5.2M
Profit Margin
-164,618.2%
ADTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.1M
Liabilities
$23.9M
Debt to equity
48.05
ADTX's short-term liabilities ($23.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADTX's short-term assets ($2.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$2.7M
Financing
$9.4M
ADTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADTX vs Biotech Stocks
Aditxt Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.